Developing clinically successful therapies with strong efficacy and tolerability relies on robust preclinical development and regulatory compliance in order to maximize patient safety and ultimately drive market success. Navigating the regulatory landscape for RNA editing can be challenging, with unforeseen hurdles to overcome on the path to commercialization.

This workshop will address:

• Understanding the attributes necessary for clinical translation of RNA editing candidates

• Navigating the regulatory path and upholding standards during preclinical and clinical development

• Identifying key hurdles on the path to commercialization and strategizing solutions to accelerate success in the clinic and on the market